February 6, 2006 -- In continuing IPO activity, QuatRx Pharmaceuticals filed to make its debut as a public company; Sanofi-Aventis delivered additional vaccine to the US government for asian flu; Corcept Therapeutics was awarded a European patent for a drug to treat psychotic major depression; Nucryst Pharma, a coating company that recently made its IPO, won European approval for an antimicrobial wound cover coating; Celtic Pharma and Neurobiological Technologies enrolled their first patient into a Phase III trials of its stroke drug; Isis Pharma began a Phase II trial of a therapy for genetically caused high cholesterol levels; Celera Genomics licensed two additional cancer antigen targets to Abbott; and on Friday, Merck received approval of its rotavirus vaccine, RotateQ. At the close, the Centient Biotech 200™ was down 19 points at 3919.62, a loss of .48%. More details...
